Infectious Disease · AntiviralRegulatory Approvalregulatorymid-term

Aurobindo Pharma's Aciclovir Supplement Application Receives Standard Review Status

Importance6/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma14 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/30/2026, 12:33:30 AM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Aurobindo Pharma's submission for Aciclovir under standard review by the FDA signifies a potential shift in the competitive landscape of the antiviral market. This could lead to increased competition and impact pricing strategies for existing aciclovir products. Regulatory context from FDA (FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)) supports the near-term read. Assessment grounded in 24 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcome of this review as it may impact market dynamics and pricing strategies for aciclovir products. The strongest clinical anchor is Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoi (ClinicalTrials.gov), mechanism alignment (io ). In Infectious Disease · Antiviral, 7 regulatory and 4 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (Roche) — sponsor/company relevance (roche). Secondary pressure from Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants. This submission indicates Aurobindo's ongoing commitment to expanding its antiviral portfolio, potentially increasing competition in the aciclovir market.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The standard review status indicates a typical timeline for approval, but any delays or issues could impact market entry and competitive positioning.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval of Aurobindo's aciclovir could affect market share and pricing for other companies in the antiviral space, potentially leading to revenue fluctuations.
Upside for Aurobindo Pharma may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Upside for Aurobindo Pharma may improve if Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities. (PubMed) delivers favorable follow-through.
Portfolio teams should monitor the outcome of this review as it may impact market dynamics and pricing strategies for aciclovir products.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's decision timeline and any potential market entry dates for Aurobindo's aciclovir product.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN AND IBUPROFEN (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoi
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Female Sexual Function After Surgery for Benign Perianal Diseases
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Genetic Analysis of Uncommon Disease Presentations in Non-US Populations
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Tioprinin for Treatment of Cystinosis
Humanexa Signalsmedium relevance
Moderate corpus alignment

Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Ginger-based formulations for allergic rhinitis disease: a systematic review and meta-analysis of experimental studies in animals and humans.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nanomaterial-based vaccines: An advanced approach against rotavirus: A review article.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Aciclovir

Commercial impact

medium

The approval of Aurobindo's aciclovir could affect market share and pricing for other companies in the antiviral space, potentially leading to revenue fluctuations.

Regulatory impact

medium

The standard review status indicates a typical timeline for approval, but any delays or issues could impact market entry and competitive positioning.

What to watch

Monitor the FDA's decision timeline and any potential market entry dates for Aurobindo's aciclovir product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.